BuyMeWhiskeyStock analysisAnswersKNSA news
Home › Stock analysis › KNSA

Kiniksa Pharmaceuticals International (KNSA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET

Updated Oct 15, 2026, 4:00 PM ET

What changed since yesterday

KNSA rises 1.4% to $79.94, a 1-month high on 3.0x normal volume. Closed at $79.94, +1.40% vs the prior close of $78.84. Day range $79.62–$82.98, opened at $79.85.

Last close$79.94+1.40%
Day range79.62–82.98
Open79.85
Volume1.48M
52-week range35.20–82.98
Avg volume (20d)574.78K

KNSA daily analysis — what happened

A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.

Oct 15, 2026 — KNSA rises 1.4% to $79.94, a 1-month high on 3.0x normal volume
Oct 14, 2026 — KNSA rises 0.4% to $78.84
Oct 13, 2026 — KNSA dips 0.9% to $78.53
Oct 12, 2026 — KNSA dips 0.7% to $79.24
Oct 9, 2026 — KNSA rises 1.3% to $79.78, a 1-month high, 7 up days in a row
Oct 8, 2026 — KNSA rises 1.0% to $78.75, 6 up days in a row
Oct 7, 2026 — KNSA rises 1.1% to $77.96, 5 up days in a row
Oct 6, 2026 — KNSA rises 1.0% to $77.09, 4 up days in a row
Oct 5, 2026 — KNSA rises 0.7% to $76.31, 3 up days in a row
Oct 2, 2026 — KNSA rises 0.8% to $75.79

KNSA latest news & SEC filings

Every SEC filing by or about KNSA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001835458-26-000012

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001532218-26-000016

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001532218-26-000014

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001741533-26-000010

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).

Source: SEC EDGAR filing 0001857177-26-000008

Sep 3, 2026 · 4 — Insider trade report (Form 4)

Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings

Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.

Source: SEC EDGAR filing 0001464583-26-000008

Jul 29, 2026 · SCHEDULE 13G — Passive stake (13G)

Passive stake (13G) — an investor reported owning more than 5%

Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.

Source: SEC EDGAR filing 0002012383-26-002783

Jul 28, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)

Quarterly report (unaudited financial statements for the quarter)

Key figures from this report aren't in the SEC's structured data yet (usually appears within a day or two).

Source: SEC EDGAR filing 0001104659-26-087545

Jul 28, 2026 · 8-K — Current report

Current report — a filing companies must make within 4 business days of a major event

This is a results-day filing: the earnings press release is attached as an exhibit.

Source: SEC EDGAR filing 0001730430-26-000031

Things to know before you trade KNSA

KNSA market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 15, 202679.8582.9879.6279.941.48M
Oct 14, 202678.1179.9677.7078.84576.50K
Oct 13, 202679.2180.0078.4578.53575.80K
Oct 12, 202680.0080.9978.8279.24340.90K
Oct 9, 202678.2480.5078.0379.78430.30K
Oct 8, 202677.1878.8375.4478.75411.60K
Oct 7, 202676.1879.2274.7077.96380.40K
Oct 6, 202676.0077.3273.8477.09378.70K
Oct 5, 202675.9776.7975.2976.31391.50K
Oct 2, 202675.5876.2274.5675.79376.30K
Oct 1, 202673.8776.1173.1475.22878.50K
Sep 30, 202676.5576.5573.7674.61650.60K
Sep 29, 202675.3276.5274.3375.73620.70K
Sep 28, 202675.0076.4274.0276.10734.10K
Sep 25, 202675.4076.0074.5375.08478.50K
Sep 24, 202676.0276.9574.4675.34433.30K
Sep 23, 202677.9978.2374.8876.08408.20K
Sep 22, 202678.0979.5477.3778.00403.90K
Sep 21, 202677.1278.7375.9078.13482.80K
Sep 18, 202678.9579.6176.9977.241.06M

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International (KNSA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LONDON. Fiscal year ends December 31. SEC CIK 1730430.

KNSA board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
L.P. 667,DirectorJun 2, 2026
Bros. Advisors Lp BakerDirectorJun 2, 2026
Felix BakerDirectorJun 2, 2026
Julian BakerDirectorJun 2, 2026
Bros. Advisors (Gp) Llc BakerDirectorJun 2, 2026
Brothers Life Sciences Lp BakerDirectorJun 2, 2026
G Bradley ColeDirectorJul 31, 2026
Richard S LevyDirectorAug 4, 2026
Thomas MalleyDirectorJun 2, 2026
Tracey L MccainDirectorJun 2, 2026
Sanj K PatelCHAIRMAN & CEOSep 3, 2026
Kimberly J PopovitsDirectorJun 2, 2026
Barry D QuartDirectorAug 21, 2026

Executive officers

NameTitleLatest filing
Dhiraj H MalkaniCHIEF STRATEGY OFFICERJul 6, 2026
Michael R MegnaCHIEF ACCOUNTING OFFICERSep 3, 2026
Ross MoatCHIEF OPERATING OFFICERSep 3, 2026
John F. PaoliniCHIEF MEDICAL OFFICERSep 3, 2026
Sanj K PatelCHAIRMAN & CEOSep 3, 2026
Mark RagosaCHIEF FINANCIAL OFFICERSep 3, 2026
Eben TessariCHIEF STRATEGY OFFICERApr 8, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
Sep 3, 2026Michael R MegnaSale4,600$80.30
Jul 29, 2026G Bradley ColeSale3,673$81.43
May 1, 2026John F. PaoliniSale37,327$53.52
May 1, 2026John F. PaoliniSale21,097$54.04
May 1, 2026Sanj K PatelSale48,565$54.02
Apr 30, 2026Sanj K PatelSale2,141$54.01
Apr 29, 2026Sanj K PatelSale22,544$54.01
Apr 28, 2026Sanj K PatelSale51,750$54.02
Apr 28, 2026Sanj K PatelSale243,596$52.02
Apr 28, 2026Sanj K PatelSale113,673$51.47
Apr 28, 2026Sanj K PatelSale74,635$50.43
Apr 28, 2026Barry D QuartSale13,099$50.10
Apr 9, 2026Ross MoatSale1,703$46.69
Apr 9, 2026Michael R MegnaSale6,625$46.69
Apr 6, 2026Barry D QuartSale6,901$50.00

KNSA financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
Dec 31, 2025$677.56M$59.01M0.75$137.99M
Dec 31, 2024$423.24M$-43.19M-0.60$25.69M
Dec 31, 2023$270.26M$14.08M0.20$13.30M
Dec 31, 2022$220.18M$183.36M2.60$5.81M
Dec 31, 2021$38.54M$-157.92M-2.30$-126.30M

Latest balance sheet: total assets $825.28M, total liabilities $219.59M, cash $189.95M (as of Mar 31, 2026).

KNSA earnings / results-day log

DateFilingClose that day
Jul 28, 20268-K Item 2.02 (results)$79.44
Apr 28, 20268-K Item 2.02 (results)$53.85
Feb 24, 20268-K Item 2.02 (results)$43.50
Jan 12, 20268-K Item 2.02 (results)$41.12
Oct 28, 20258-K Item 2.02 (results)$39.43
Jul 29, 20258-K Item 2.02 (results)$30.37
Apr 29, 20258-K Item 2.02 (results)$25.88
Feb 25, 20258-K Item 2.02 (results)$19.72
Jan 13, 20258-K Item 2.02 (results)$18.17
Oct 29, 20248-K Item 2.02 (results)$23.26
Jul 23, 20248-K Item 2.02 (results)—
Apr 23, 20248-K Item 2.02 (results)—

Related stocks · Pharmaceutical Preparations

Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)

Popular today

Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)

More on KNSA

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.